Clinical Trials Browser

Has results × Has announcements × Metastatic Castration-resistant Prostate Cancer × Clear all

NCT03732820 2026-06-02

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Phase 3 Active not recruiting

895 enrolled 19 charts 1 FDA

Metastatic Castration-resistant Prostate Cancer

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Phase 3 Completed

387 enrolled 16 charts 1 FDA

Metastatic Castration-resistant Prostate Cancer